Notice of the State Drug Administration on the Recognition of the Second Batch of Key Laboratories

Beijing, Tianjin, Hebei Province, Inner Mongolia Autonomous Region, Liaoning Province, Jilin Province, Heilongjiang Province, Jiangsu Province, Zhejiang Province, Anhui Province, Fujian Province, Shandong Province, Henan Province, Hubei Province, Hunan Province, Guangdong Province, Guangxi Zhuang Autonomous Region, Hainan Province, Sichuan Province, Tibet Autonomous Region, Shaanxi Province, Qinghai Province, Xinjiang Uygur Autonomous Region and Drug Administration:

In order to accelerate the construction of key laboratories of the State Drug Administration to meet the strategic needs of China's innovative development and regulatory science of drugs, medical devices and cosmetics, the State Drug Administration organized the completion of the second batch of key laboratories of the review, is now recognized and released “the second batch of key laboratories list of the State Drug Administration”. Please ask the competent department of each key laboratory and each relying unit to do a good job in organizing the operation and management and guarantee work in accordance with the “State Drug Administration Key Laboratory Management Measures” (State Drug Administration Science and Technology Outside 〔2019〕 No. 56) and the requirements of the relevant documents, and constantly improve the level of scientific research to better protect and promote public health.